The Sentinel


Thursday, June 29, 2017

President's Message - June 2017

Dear Colleagues,

As those who attended the American Society of Clinical Oncology’s (ASCO) 2017 Annual Meeting earlier this month can attest, the field of cancer immunotherapy continues to explode, with more than 80 immunotherapy educational sessions and abstract presentations over five days, and many poster presentations. Cancer immunotherapy has emerged as a clinically beneficial option for many patients.

For more than 33 years, the Society for Immunotherapy of Cancer (SITC) has been the leader in cancer immunotherapy – long before the world would see the impact this treatment modality has made in the fight against cancer. The society’s Annual Meeting & Pre-Conference Programs (SITC 2017) is the largest meeting dedicated solely to the field. This premier conference brings together leading cancer immunotherapy experts from around the world. SITC 2017 promises unparalleled cutting-edge research and networking opportunities. Register today for SITC 2017, scheduled on Nov. 8-12.   You can look forward to five days of state of the science presentations at the SITC annual meeting this fall, where each presentation and poster revolves around cancer immunotherapy.

SITC has always strongly supported the growth and development of young investigators, as the future of cancer immunotherapy is rooted in research and education. Take a look at these opportunities designed to ensure that talented, innovative professionals continue to be attracted to careers in this treatment modality.

Get involved and share these opportunities with a young investigator in your network.
Cancer immunotherapy saves lives and is forever changing what it means to have cancer. Early career scientists provide critical support in the research and innovation in this evolving field.

Thank you for your continued support.

Best wishes,

Lisa H. Butterfield, PhD

SITC President